Chimerix Inc. (CMRX)’s Financial Results Comparing With Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)

As Biotechnology companies, Chimerix Inc. (NASDAQ:CMRX) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) are our subject to compare. And more specifically their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chimerix Inc. 7.22M 14.46 69.47M -1.55 0.00 Paratek Pharmaceuticals Inc. 17.12M 12.12 112.36M -3.64 0.00 Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Chimerix Inc. and Paratek Pharmaceuticals Inc.

Profitability

Table 2 provides the net margins, return on equity and return on assets of the two firms. Net Margins Return on Equity Return on Assets Chimerix Inc. -962.19% -36.5% -34.7% Paratek Pharmaceuticals Inc. -656.31% -132.5% -44.6% Volatility and Risk

A 1.36 beta means Chimerix Inc.’s volatility is 36.00% more than Standard and Poor’s 500’s volatility. Paratek Pharmaceuticals Inc.’s 1.71 beta is the reason why it is 71.00% more volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Chimerix Inc. are 19.9 and 19.9. Competitively, Paratek Pharmaceuticals Inc. has 11.4 and 11.4 for Current and Quick Ratio. Chimerix Inc.’s better ability to pay short and long-term obligations than Paratek Pharmaceuticals Inc.

Analyst Recommendations

The Recommendations and Ratings for Chimerix Inc. and Paratek Pharmaceuticals Inc. are featured in the next table.

Chimerix Inc. has a consensus target price of $3.5, and a 70.73% upside potential. Competitively Paratek Pharmaceuticals Inc. has a consensus target price of $21.25, with potential upside of 232.03%. Based on the analysts belief we can conclude, Paratek Pharmaceuticals Inc. is looking more favorable than Chimerix Inc.

Insider & Institutional Ownership

The shares of both Chimerix Inc. and Paratek Pharmaceuticals Inc. are owned by institutional investors at 81% and 77.7% respectively. 1.4% are Chimerix Inc.’s share owned by insiders. Comparatively, 3.1% are Paratek Pharmaceuticals Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Chimerix Inc. 16.16% -1.29% -33.53% -45.11% -52.97% -10.51% Paratek Pharmaceuticals Inc. -6.09% 0.67% -8.98% -32.44% -46.95% 32.36% For the past year Chimerix Inc. had bearish trend while Paratek Pharmaceuticals Inc. had bullish trend.

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companyÂ’s lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Tags:

Click Here to Continue!


Add a Comment

Your email address will not be published. Required fields are marked *